Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAIN1: Oral Azacitidine Maintenance in AML Patients with SDOH Disparities
NCT06370000Phase 4Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Virginia Commonwealth University. Started Nov 2024; status: recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06370000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370000.